Heyholder
‹ Activism Filings

Mezzion Pharma Co., Ltd. Q3 revenue KRW 2.4 billion, operating loss KRW 4.2 billion

Mezzion Pharma Co., Ltd.· Periodic Report

AI summary · Not investment advice

Mezion sold KRW 2.4 billion in Q3 and lost KRW 4.2 billion from its main business; sales rose 13.7% from a year earlier and 9.9% from the previous quarter.

Operating profit · 3 months

KRW -4.2 billion

Key facts

Revenue (3 months)
KRW 2.4 billion
Net income (3 months)
KRW -7.4 billion
Period
Q3 (cumulative 2026.01.01 ~ 2026.09.30)
Revenue (prior-year 3 months)
KRW 2.1 billion
Revenue (year to date)
KRW 6.6 billion
Operating profit (prior-year 3 months)
KRW -4.7 billion
Operating profit (year to date)
KRW -13.3 billion
Net income (prior-year 3 months)
KRW -5.1 billion
Net income (year to date)
KRW -5.1 billion

Commentary

AI commentary · Not investment advice

What happened

Mezion reported its consolidated results for the 3rd quarter (July to September).

In the company's terms

Sales for the 3 months were KRW 2.42 billion. That is 13.7% more than the same 3 months a year earlier (KRW 2.13 billion) and 9.9% more than the previous quarter. Sales for the year so far are KRW 6.64 billion.

What changes for shareholders

Operating profit (profit from the core business) was a loss of KRW 4.21 billion for the 3 months. A year earlier, the same period had a loss of KRW 4.65 billion. The loss for the year so far is KRW 13.31 billion.

Net income (the final profit after taxes and all other items) was a loss of KRW 7.45 billion for the 3 months. The previous quarter had a profit, so this is a swing to a loss. The same period a year earlier had a loss of KRW 5.13 billion. The loss for the year so far is KRW 5.07 billion.

Comments

No comments yet

Comments from shareholders will appear here.